Capital DailyCapital Daily
Markets · Investing · Business
Capital DailyCapital Daily
Finance

Trading in Pre-IPO Companies Is Suddenly Big Business. Here's Why Hyperliquid Could Be the Biggest Winner.

The platform is now home to the latest mega pre-IPO perpetual future listing.

Trading in Pre-IPO Companies Is Suddenly Big Business. Here's Why Hyperliquid Could Be the Biggest Winner.

Published July 19, 2026 · Category: Finance

Overview

A company you've probably never heard of -- ChangXin Memory Technologies -- priced its soon-to-launch stock listing this week in Shanghai at 8.66 yuan a share, valuing China's biggest memory chipmaker at almost $85 billion. Nearly two weeks before those shares are set for an initial public offering (IPO), a contract tracking one of them is changing hands on Hyperliquid (CRYPTO: HYPE), a decentralized derivatives exchange. Retail investors in China and practically everywhere else are scrambling to get exposure using its network.

Pre-IPO perpetual futures -- contracts that track a private company's expected share price and never expire -- are quickly becoming more popular. Cerebras Systems and Space Exploration Technologies each had perputal futures trading before listing, and the next set of hotly anticipated IPOs, specifically OpenAI and Anthropic, have them now. Hyperliquid is currently positioned to be the biggest platform for trading those pre-IPO perpetuals, and here's why.

Image source: Getty Images.

Details

Continue reading

Source

Originally published at www.fool.com.

Related Articles

CD
Capital Daily Newsroom

Capital Daily covers markets, crypto and commodities for Asia & the Middle East — tier-1 desk research, AI-driven analysis, institutional-grade data. Tip our newsroom: [email protected]

Email the newsroom →
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.